April 2022 - Dave Ricks | Eli Lilly and Company

Eli Lilly CEO David Ricks on GLP-1 and obesity drugsПодробнее

Eli Lilly CEO David Ricks breaks down second-quarter earnings and drug pipelineПодробнее

Eli Lilly CEO: We expect to launch five new medicines in 2022Подробнее

Dave Ricks, Chair & CEO of Eli Lilly, Discusses GLP-1Подробнее

Eli Lilly CEO David Ricks on Q1 earnings: This will be a year of both growth and investmentПодробнее

3 Core Values at Lilly via David RicksПодробнее

Eli Lilly CEO Reiterates 5% Revenue Growth TargetПодробнее

Eli Lilly CEO Dave Ricks Talks Fighting Obesity, Developing New Drugs | Bloomberg TalksПодробнее

Footprints: Dave RicksПодробнее

Vast utility for weight loss drugs will more than pay for themselves, says Eli Lilly CEO David RicksПодробнее

David Ricks, Chairman and CEO, Eli Lilly and CompanyПодробнее

Lilly Manufacturing: Who We AreПодробнее

Eli Lilly CEO: Trump policies could help expand operations in U.S.Подробнее

Eli Lilly Alzheimer's Drug Does Not Slow Memory Loss | Squawk Box | CNBCПодробнее

Why Work at Eli Lilly and Company?Подробнее

Eli Lilly CEO on drug prices: Patients are paying too much out-of-pocket costsПодробнее

Coronavirus: Eli Lilly CEO David Ricks on development of therapiesПодробнее

Eli Lilly CEO on 1Q Results, Drug Pricing, Pharma MarginsПодробнее